Kymera Therapeutics

Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan

WATERTOWN, Mass., July 08, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Leigh Morgan to its Board of